Nervonik
Designed For Motion
- Headquarters
- Los Angeles, California
- Employees
- 1–10
- Business Model
- B2B
- Website
- nervonik.com
- Last Round
- SAFEMar 2025
- Rounds
- 2
About
Nervonik is developing next-generation peripheral nerve stimulation (PNS) technology featuring a novel, patented trifecta system that eliminates technical barriers to biosensing in high-motion applications. The company's miniaturized devices address limitations of existing PNS devices by improving lead placement, programming flexibility, energy efficiency, and long-term efficacy. Nervonik's technology is currently under development and has not yet received FDA clearance or approval.
Summary
Nervonik is a Healthcare company based in Los Angeles, United States. Its most recent funding was a SAFE round in Mar 2025. Investors include ShangBay Capital, Camford Capital and Joyance Partners.
Tech & App Stack
5 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Mar 2025
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Largest private manufacturer and distributor of medical-surgical products serving healthcare prov...
Healthcare cost management company providing data analytics and network-based payment solutions t...
American dietary supplements company owning Nature's Bounty, Solgar, and Puritan's Pride brands; ...
OneOncology empowers oncology practices with advanced tools and capabilities to help physicians d...
World-leading Canadian cannabis company cultivating and selling medicinal and recreational cannab...
Healthcare company in Europe